1 day+0.76%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.65
Extreme 1.65
2.66
3 years 0.89
Extreme 0.89
8.49
5 years 0.89
Extreme 0.89
28.24
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 28/01/2026
Director TitleAgeSince
Director/Board Member - 28/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
28/1/26 Issuer sale

Chief Executive Officer

1,167,586 2.7085%
28/1/26
BVF Partners LP
TenderCompany 10,166,943 23.5846%
28/1/26 Issuer sale

Chairman

7,500 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--% - - 114M
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.13%+2.09%+25.76%+51.97% 45.03B
-1.39%-5.08%+15.70%+114.12% 42.17B
+1.38%-5.21%+221.29%+901.16% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+15.18%+60.27%+49.33% 26.5B
Average -0.44%+1.98%+46.34%+156.58% 42.59B
Weighted average by Cap. -0.66%+1.72%+43.38%+155.48%
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Repare Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. RPTX Stock